Testing a new drug combination for advanced lung cancer

Plain-English translation of NCT07306624 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of two medications: , given together to treat advanced lung cancer that has stopped responding to previous chemotherapy or immunotherapy. The study wants to learn whether this medication combination is safe and whether it can help shrink tumors in people whose cancer is resistant to standard treatments. About 62 people will participate.

Many people with advanced lung cancer eventually find that standard treatments stop working. This trial exists because researchers believe that combining this medication with a well-established chemotherapy drug might offer a new option for patients who have run out of other treatment choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with stage 3 or 4 non-small cell lung cancer that has returned or spread
your cancer has a specific marker (called BTN1A1 with a TPS score of at least 50)
your cancer has progressed after at least one prior treatment with platinum-based chemotherapy and/or immunotherapy
you are in good enough overall health to tolerate treatment (ECOG performance status 0–1)
your heart, liver, and kidneys are working well enough for this study
you have a life expectancy of at least 3 months

You likely don't qualify if…

you are allergic to any ingredient in either study medication
you have received Docetaxel before as a palliative (comfort) treatment
you received chemotherapy, targeted therapy, or monoclonal antibodies very recently (within the last 2–4 weeks)
you have an active, uncontrolled infection or fever requiring intravenous antibiotics
you have unstable heart disease, a recent heart attack, or uncontrolled high blood pressure

What participation looks like

You will receive the two medications as part of a treatment regimen over a period of time during regular clinic visits. The research team will monitor you closely with blood tests, scans, and physical exams to check how well the treatment is working and to watch for any side effects. You will also need to provide a tissue sample (archived or newly collected) to help researchers understand your cancer better.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(5 sites)

South Korea

The Catholic University of Korea St. Vincent's Hospital, Gyeonggi-do

Kangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Bundang Hospital, Seoul